Clinical Efficacy and Safety of Yellow Oil Formulations 3 and 4 versus Indomethacin Solution in Patients with Symptomatic Osteoarthritis of the Knee: A Randomized Controlled Trial

Table 2

Efficacy outcome assessment.

	YOF3	YOF4	INDO	value^1
Mean change of VAS pain
MITT analysis	−25.06 ± 13.91	−18.50 ± 16.06	−23.38 ± 10.05	0.169
PP analysis	−25.90 ± 14.36	−20.08 ± 14.18	−23.38 ± 10.05	0.259
Mean change of VAS stiffness
MITT analysis	−19.59 ± 11.74	−21.38 ± 16.05	−20.03 ± 13.86	0.881
PP analysis	−20.45 ± 11.87	−23.76 ± 10.75	−20.03 ± 13.86	0.484
Mean change of time taken to climb up 10 steps
MITT analysis	−1.06 ± 2.45	−1.08 ± 1.74	−1.88 ± 2.34	0.264
PP analysis	−1.03 ± 2.43	−1.16 ± 1.72	−1.88 ± 2.34	0.284
Mean change of time up and go test
MITT analysis	−1.34 ± 1.83	−1.15 ± 1.95	−1.44 ± 1.72	0.839
PP analysis	−1.28 ± 1.89	−1.32 ± 1.80	−1.44 ± 1.72	0.936
Mean change of KOOS pain
MITT analysis	13.78 ± 12.56	9.69 ± 14.91	13.81 ± 14.64	0.456
PP analysis	14.59 ± 12.91	11.28 ± 12.78	13.81 ± 14.64	0.651
Mean change of KOOS other symptoms
MITT analysis	10.75 ± 12.02	7.23 ± 14.64	13.13 ± 11.77	0.220
PP analysis	10.14 ± 12.24	8.08 ± 14.27	13.13 ± 11.77	0.324
Mean change of KOOS activities of daily living
MITT analysis	11.53 ± 12.88	9.54 ± 16.64	12.91 ± 14.07	0.678
PP analysis	11.59 ± 13.53	11.32 ± 14.22	12.91 ± 14.07	0.896
Mean change of KOOS sport and recreation function
MITT analysis	11.41 ± 15.72	12.69 ± 17.62	13.13 ± 16.35	0.911
PP analysis	11.38 ± 16.47	13.60 ± 17.35	13.13 ± 16.35	0.872
Mean change of KOOS knee-related quality of life
MITT analysis	8.31 ± 13.57	4.81 ± 18.14	9.16 ± 13.21	0.516
PP analysis	7.69 ± 13.89	6.24 ± 16.95	9.16 ± 13.21	0.755

Data shown as mean ± SD. ¹One-way ANOVA.